Figure 8.

PAR1 inhibitor reduced rKLK6-mediated tumor growth and lung metastasis. (A–E) B16F10 cells (1 × 10⁶) were subcutaneously injected into KLK6−/− mice. After 1 h, DMSO (control), rKLK6 (10 mg/kg), or rKLK6 plus PAR1 (5 mM/kg) were injected every other day for 10 days. (A) Representative photograph of the tumors. The tumor volume (B) and tumor weight (C) were measured as described in the Materials and Methods. The levels of serum TNF-α (D) and CXCL1 (E) were measured by ELISA. (F,J) B16F10 cells (5 × 10⁵) were injected into the tail vein of WT mice. After 1 h, DMSO (control), rKLK6 (10 mg/kg), or rKLK6 plus PAR1 (5 mM/kg) were injected every other day for 10 days. (F) Representative photograph of metastatic lung nodules. The number of metastatic lung nodules (G) were calculated as described in the Materials and Methods. (H) The weight of lungs with metastasized nodules:body weight. The levels of serum TNF-α (I) and CXCL1 (J) were analyzed by ELISA. ** p < 0.01 and * p < 0.05 (Student’s t-test). Data are representative of three experiments.